Ascendis Pharma A/S (ASND) · Insider trading
What Ascendis Pharma's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$777,068
2 insiders, 9 trades
Sold, 12 months
$5.51M
3 insiders, 0% under a plan
Net, 12 months
−$4.74M
bought less sold
Latest filing
2026-09-09
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Jensen Flemming SteenSee Remarks | – | $4.64M | 1 | 2026-05-11 | 0 |
| Bodenhoff MadsSVP & PAO | – | $810,570 | 1 | 2026-09-08 | 0 |
| Bienaime Jean JacquesDirector | $699,338 | – | 7 | 2026-08-14 | 2,000 |
| Smith Scott ThomasEVP & Chief Financial Officer | $77,730 | – | 2 | 2026-06-02 | 4,367 |
| Holtug LarsDirector | – | $62,335 | 1 | 2026-09-02 | 4,000 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Bodenhoff MadsSVP & PAO | Sale | 3,000 | 270.19 | $810,570 | 0 | Form 4 |
| 2026-09-02 | Holtug LarsDirector | Sale | 236 | 264.13 | $62,335 | 4,000 | Form 4 |
| 2026-08-14 | Bienaime Jean JacquesDirector | Buy | 1,100 | 245.85 | $270,435 | 2,000 | Form 4 |
| 2026-08-14 | Bienaime Jean JacquesDirector | Buy | 900 | 246.91 | $222,219 | 2,900 | Form 4 |
| 2026-06-02 | Smith Scott ThomasEVP & Chief Financial Officer | Buy | 100 | 219.00 | $21,900 | 4,367 | Form 4 |
| 2026-05-29 | Smith Scott ThomasEVP & Chief Financial Officer | Buy | 250 | 223.32 | $55,830 | 4,267 | Form 4 |
| 2026-05-29 | Bienaime Jean JacquesDirector | Buy | 200 | 223.76 | $44,752 | 600 | Form 4 |
| 2026-05-29 | Bienaime Jean JacquesDirector | Buy | 200 | 222.30 | $44,460 | 800 | Form 4 |
| 2026-05-29 | Bienaime Jean JacquesDirector | Buy | 100 | 223.50 | $22,350 | 900 | Form 4 |
| 2026-05-26 | Bienaime Jean JacquesDirector | Buy | 200 | 236.24 | $47,248 | 200 | Form 4 |
| 2026-05-26 | Bienaime Jean JacquesDirector | Buy | 200 | 239.37 | $47,874 | 400 | Form 4 |
| 2026-05-11 | Jensen Flemming SteenSee Remarks | Sale | 19,460 | 238.49 | $4.64M | 0 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
1 × option exercise
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-08 | Bodenhoff MadsSVP & PAO | Option exercise M | +3,000 | 110.00 | 3,000 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.